Aktienanalyse wird geladen …
BMY · NYSE · Pharmaceuticals · USA
62,86 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 48,19 Mrd. | 7,05 Mrd. | 3,46 $ | 2,04 Mrd. | 8,8 Mio · 0,4 % | — | 71,1 % | 14,6 % | 6,30 $ | 0,27 $ | 2,49 $ |
| 2024 | 48,3 Mrd. | -8,95 Mrd. | -4,41 $ | 2,03 Mrd. | 8,1 Mio · 0,4 % | — | 71,1 % | -18,5 % | 6,88 $ | 0,25 $ | 2,42 $ |
| 2023 | 45,01 Mrd. | 8,03 Mrd. | 3,86 $ | 2,08 Mrd. | 8,2 Mio · 0,4 % | 76,2 Mio · 3,7 % | 76,2 % | 17,8 % | 6,09 $ | 0,25 $ | 2,31 $ |
| 2022 | 46,16 Mrd. | 6,33 Mrd. | 2,95 $ | 2,15 Mrd. | 7,3 Mio · 0,3 % | 106 Mio · 5 % | 78 % | 13,7 % | 5,57 $ | 0,21 $ | 2,19 $ |
| 2021 | 46,39 Mrd. | 6,99 Mrd. | 3,12 $ | 2,25 Mrd. | 9,3 Mio · 0,4 % | — | 78,6 % | 15,1 % | 6,79 $ | 0,26 $ | 2,01 $ |
| 2020 | 42,52 Mrd. | -9,02 Mrd. | -3,99 $ | 2,26 Mrd. | 12,4 Mio · 0,5 % | — | 72,3 % | -21,2 % | 5,89 $ | 0,34 $ | 1,84 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 12,97 Mrd. | 3,32 Mrd. | 1,62 $ | 2,05 Mrd. | 25,6 % | 1,51 $ |
| Q1 2026 | 11,49 Mrd. | 2,68 Mrd. | 1,31 $ | 2,05 Mrd. | 23,3 % | 0,37 $ |
| Q4 2025 | 12,5 Mrd. | 1,09 Mrd. | 0,53 $ | 2,04 Mrd. | 8,7 % | 0,79 $ |
| Q3 2025 | 12,22 Mrd. | 2,2 Mrd. | 1,08 $ | 2,04 Mrd. | 18 % | 2,94 $ |
| Q2 2025 | 12,27 Mrd. | 1,31 Mrd. | 0,64 $ | 2,04 Mrd. | 10,7 % | 1,74 $ |
| Q1 2025 | 11,2 Mrd. | 2,46 Mrd. | 1,20 $ | 2,04 Mrd. | 21,9 % | 0,83 $ |
| Q4 2024 | 12,34 Mrd. | 72 Mio. | 0,04 $ | — | 0,6 % | 1,99 $ |
| Q3 2024 | 11,89 Mrd. | 1,21 Mrd. | 0,60 $ | 2,03 Mrd. | 10,2 % | 2,59 $ |
Bristol-Myers Squibb Says Zenbexus Combination Doubles MRD-Negative Complete Response in Multiple Myeloma Trial
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest BMY und jede andere Aktie unbegrenzt.